Related Experiment Video

Updated: Jun 22, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment

E Dimou1, J Booij, M Rodrigues

  • 1Department of Nuclear Medicine, University Hospital, Vienna, Austria.

Current Alzheimer Research
|June 13, 2009
PubMed

Insights

Positron emission tomography (PET) with new amyloid tracers can visualize amyloid beta in Alzheimer's disease (AD) brains. This technique aids in early AD diagnosis and predicting mild cognitive impairment (MCI) to AD conversion.

Area of Science:

  • Neuroscience
  • Medical Imaging
  • Radiochemistry

Background:

  • Alzheimer's disease (AD) is the most common dementia, marked by cognitive decline.
  • Differentiating AD from other dementias and predicting mild cognitive impairment (MCI) progression to AD are clinical challenges.
  • Amyloid beta (Abeta) is a key pathological hallmark of AD.

Purpose of the Study:

  • To review the advancements in Positron Emission Tomography (PET) and radiopharmaceuticals for amyloid imaging in AD.
  • To explore the potential of in vivo amyloid imaging for early diagnosis and treatment evaluation in AD.
  • To assess the role of Abeta in predicting MCI conversion to AD.

Main Methods:

  • Review of recent developments in PET imaging technology.
  • Discussion of novel radiopharmaceuticals for detecting fibrillar Abeta.
  • Analysis of studies on the utility of PET imaging in AD and MCI.

Main Results:

  • Successful development of amyloid tracers for PET imaging allows measurement of fibrillar Abeta load in living brains.
  • PET imaging shows promise for early and differential diagnosis of AD.
  • Abeta imaging may aid in predicting the conversion of MCI to AD.

Conclusions:

  • PET imaging with amyloid tracers is emerging as a vital tool for Alzheimer's disease diagnosis and management.
  • In vivo amyloid imaging can potentially improve the prediction of MCI to AD conversion.
  • Further research and clinical application of PET imaging are expected to advance AD understanding and treatment.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...